Wipfli Financial Advisors’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Wipfli Financial Advisors’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1K	Buy	+109	New	+$1.43K	﹤0.01%	2532

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Wipfli Financial Advisors's KNTE Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2022: 109 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2532 among its holdings.

84 funds tracked by Wall St. Rank hold KNTE as of Q3 2022.

Wipfli Financial Advisors held 109 shares of Kinnate Biopharma Inc. Common Stock worth $1K as of Q3 2022.
Kinnate Biopharma Inc. Common Stock was a new Wipfli Financial Advisors position in Q3 2022.
Kinnate Biopharma Inc. Common Stock made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2532 holding.
84 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.